SBH
PCRX icon

Segall Bryant & Hamill’s Pacira BioSciences PCRX Stock Holding History

Segall Bryant & Hamill’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$885K Buy
34,892
+5,356
+18% +$127K 0.01% 550
2026
Q1 		$668K Hold
29,536
– – 0.01% 540
2025
Q4 		$764K Sell
29,536
-147
-0.5% -$3.5K 0.01% 524
2025
Q3 		$765K Sell
29,683
-82
-0.3% -$2.01K 0.01% 521
2025
Q2 		$711K Sell
29,765
-2,120
-7% -$53.4K 0.01% 525
2025
Q1 		$792K Sell
31,885
-176
-0.5% -$4.21K 0.01% 522
2024
Q4 		$604K Hold
32,061
– – 0.01% 546
2024
Q3 		$483K Buy
+32,061
New +$548K 0.01% 545
2023
Q4 		– Sell
-137,925
Closed -$4.23M – 436
2023
Q3 		$4.23M Buy
137,925
+43,481
+46% +$1.57M 0.05% 347
2023
Q2 		$3.78M Buy
94,444
+397
+0.4% +$16.4K 0.04% 375
2023
Q1 		$3.84M Buy
94,047
+1,165
+1% +$46.3K 0.04% 375
2022
Q4 		$3.59M Buy
92,882
+6,428
+7% +$313K 0.04% 368
2022
Q3 		$4.6M Buy
86,454
+1,711
+2% +$95.1K 0.05% 326
2022
Q2 		$4.94M Buy
84,743
+25,078
+42% +$1.64M 0.06% 315
2022
Q1 		$4.55M Buy
59,665
+149
+0.3% +$9.93K 0.04% 345
2021
Q4 		$3.58M Buy
59,516
+2,772
+5% +$153K 0.03% 364
2021
Q3 		$3.18M Sell
56,744
-4,490
-7% -$259K 0.03% 412
2021
Q2 		$3.71M Buy
61,234
+2,722
+5% +$172K 0.04% 375
2021
Q1 		$4.1M Sell
58,512
-259
-0.4% -$18.5K 0.04% 372
2020
Q4 		$3.52M Sell
58,771
-977
-2% -$57.2K 0.04% 350
2020
Q3 		$3.59M Buy
59,748
+39,018
+188% +$2.27M 0.05% 303
2020
Q2 		$1.09M Buy
20,730
+451
+2% +$18.8K 0.02% 419
2020
Q1 		$679K Sell
20,279
-1,444
-7% -$60K 0.01% 520
2019
Q4 		$985K Sell
21,723
-1,178
-5% -$50K 0.02% 524
2019
Q3 		$873K Buy
22,901
+372
+2% +$14.8K 0.01% 544
2019
Q2 		$979K Buy
22,529
+5,619
+33% +$239K 0.01% 532
2019
Q1 		$643K Buy
16,910
+433
+3% +$16.9K 0.01% 617
2018
Q4 		$709K Sell
16,477
-142
-0.9% -$6.63K 0.01% 583
2018
Q3 		$817K Sell
16,619
-52
-0.3% -$2.25K 0.01% 585
2018
Q2 		$534K Buy
+16,671
New +$576K 0.01% 661

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Segall Bryant & Hamill's PCRX Position: Q2 2026 in Review

Segall Bryant & Hamill increased its Pacira BioSciences (PCRX) stake by 18% in Q2 2026, buying an estimated $127K and bringing the position to 34,892 shares worth $885K. The position accounts for 0.01% of the portfolio, ranked #550.

Segall Bryant & Hamill first reported a position in PCRX in Q2 2018 and has held it in 30 quarters since. The position peaked at $4.94M in Q2 2022. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Segall Bryant & Hamill held 34,892 shares of Pacira BioSciences worth $885K as of Q2 2026.
  • Segall Bryant & Hamill bought 5,356 Pacira BioSciences shares in Q2 2026, an estimated $127K.
  • Pacira BioSciences made up 0.01% of Segall Bryant & Hamill's portfolio in Q2 2026, its #550 holding.
  • Segall Bryant & Hamill first reported a position in Pacira BioSciences in Q2 2018 and has held it in 30 quarters since.
  • Segall Bryant & Hamill's Pacira BioSciences position peaked at $4.94M in Q2 2022.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.